BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jang J, Han Y, Lee H, Kim S, Kwon W, Lee K, Oh D, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of Surgery 2018;268:215-22. [DOI: 10.1097/sla.0000000000002705] [Cited by in Crossref: 205] [Cited by in F6Publishing: 98] [Article Influence: 51.3] [Reference Citation Analysis]
Number Citing Articles
1 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
2 Huguet F, Rivin Del Campo E, Orthuon A, Mornex F, Bessières I, Guimas V, Vendrely V. Radiation therapy of pancreatic cancers. Cancer Radiother 2021:S1278-3218(21)00199-2. [PMID: 34953706 DOI: 10.1016/j.canrad.2021.08.010] [Reference Citation Analysis]
3 Roth S, Springfeld C, Diener MK, Tjaden C, Knebel P, Klaiber U, Michalski CW, Mieth M, Jäger D, Büchler MW, Hackert T. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. BMJ Open 2019;9:e028696. [PMID: 31434770 DOI: 10.1136/bmjopen-2018-028696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Janssen QP, van Dam JL, Kivits IG, Besselink MG, van Eijck CHJ, Homs MYV, Nuyttens JJME, Qi H, van Santvoort HJ, Wei AC, de Wilde RF, Wilmink JW, van Tienhoven G, Groot Koerkamp B. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2021. [PMID: 34142290 DOI: 10.1245/s10434-021-10276-8] [Reference Citation Analysis]
5 Nie C, Zhang Y, Zhou G, Zhou T, Zhu T, Wang B, Chen S, Wang H, Yu Z, Jing L, Sun J. Analysis of the efficacy of transcatheter arterial infusion chemotherapy in the treatment of pancreatic carcinoma. J Interv Med 2021;4:21-6. [PMID: 34805943 DOI: 10.1016/j.jimed.2020.10.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, Tsai S, Ferrone CR, B Fleming J, Chang DT, Crane C, Koong AC, Oar A, Parikh P, Erickson B, Hoffe S, Goodman KA. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. J Clin Oncol 2021;39:3773-7. [PMID: 34623894 DOI: 10.1200/JCO.21.01220] [Reference Citation Analysis]
8 Azab B, Macedo FI, Chang D, Ripat C, Franceschi D, Livingstone AS, Yakoub D. The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. Clin Med Insights Oncol 2020;14:1179554920919402. [PMID: 32669884 DOI: 10.1177/1179554920919402] [Reference Citation Analysis]
9 Ren X, Wei X, Ding Y, Qi F, Zhang Y, Hu X, Qin C, Li X. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review. Onco Targets Ther 2019;12:733-44. [PMID: 30774360 DOI: 10.2147/OTT.S190810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kim SS, Lee S, Lee HS, Bang S, Park MS. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Abdom Radiol (NY) 2021;46:655-66. [PMID: 32748250 DOI: 10.1007/s00261-020-02661-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Leal AD, Messersmith WA, Lieu CH. Neoadjuvant treatment of localized pancreatic adenocarcinoma. J Gastrointest Oncol 2021;12:2461-74. [PMID: 34790407 DOI: 10.21037/jgo-20-250] [Reference Citation Analysis]
12 Mikulic D, Mrzljak A. Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. World J Clin Cases 2021; 9(20): 5398-5407 [PMID: 34307593 DOI: 10.12998/wjcc.v9.i20.5398] [Reference Citation Analysis]
13 Giovinazzo F, Soggiu F, Jang JY, Versteijne E, van Tienhoven G, van Eijck CH, Han Y, Choi SH, Kang CM, Zalupski M, Ahmad H, Yentz S, Helton S, Rose JB, Takishita C, Nagakawa Y, Abu Hilal M. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.Front Oncol. 2020;10:1112. [PMID: 32850319 DOI: 10.3389/fonc.2020.01112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, Wang K, Guo S, Zhang H, Jin G. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol 2019;14:52. [PMID: 30917842 DOI: 10.1186/s13014-019-1254-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G;  Dutch Pancreatic Cancer Group. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38:1763-1773. [PMID: 32105518 DOI: 10.1200/jco.19.02274] [Cited by in Crossref: 174] [Cited by in F6Publishing: 89] [Article Influence: 87.0] [Reference Citation Analysis]
16 Perri G, Prakash LR, Katz MHG. Response to Preoperative Therapy in Localized Pancreatic Cancer. Front Oncol 2020;10:516. [PMID: 32351893 DOI: 10.3389/fonc.2020.00516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Latenstein AEJ, van Roessel S, van der Geest LGM, Bonsing BA, Dejong CHC, Groot Koerkamp B, de Hingh IHJT, Homs MYV, Klaase JM, Lemmens V, Molenaar IQ, Steyerberg EW, Stommel MWJ, Busch OR, van Eijck CHJ, van Laarhoven HWM, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Ann Surg Oncol 2020;27:2516-24. [PMID: 32052299 DOI: 10.1245/s10434-020-08235-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
18 Bonds M, Rocha FG. Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. J Clin Med 2019;8:E1205. [PMID: 31409042 DOI: 10.3390/jcm8081205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
19 Nishiwada S, Sho M, Cui Y, Yamamura K, Akahori T, Nakagawa K, Nagai M, Nakamura K, Takagi T, Ikeda N, Li W, Baba H, Goel A. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Int J Cancer 2021;148:769-79. [PMID: 32895958 DOI: 10.1002/ijc.33284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Jung JH, Choi DW, Yoon S, Yoon SJ, Han IW, Heo JS, Shin SH. Three Thousand Consecutive Pancreaticoduodenectomies in a Tertiary Cancer Center: A Retrospective Observational Study. J Clin Med 2020;9:E2558. [PMID: 32784559 DOI: 10.3390/jcm9082558] [Reference Citation Analysis]
21 McCaw ZR, Tian L, Kim DH, Wei LJ. Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)". Ann Surg 2019;270:e48-50. [PMID: 30499804 DOI: 10.1097/SLA.0000000000003115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tomishima K, Ishii S, Fujisawa T, Ikemura M, Ota H, Kabemura D, Ushio M, Fukuma T, Takahashi S, Yamagata W, Takasaki Y, Suzuki A, Ito K, Saito H, Nagahara A, Isayama H. Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer. Cancers (Basel) 2021;13:4224. [PMID: 34439377 DOI: 10.3390/cancers13164224] [Reference Citation Analysis]
23 Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589 [PMID: 34754153 DOI: 10.3748/wjg.v27.i39.6572] [Reference Citation Analysis]
24 Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS One 2019;14:e0212805. [PMID: 30817807 DOI: 10.1371/journal.pone.0212805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
25 . Scientific surgery. British Journal of Surgery 2018;105:1697-1697. [DOI: 10.1002/bjs.11013] [Reference Citation Analysis]
26 Gits HC, Tang AH, Harmsen WS, Bamlet WR, Graham RP, Petersen GM, Smyrk TC, Mahipal A, Kowalchuk RO, Ashman JB, Rule WG, Owen D, Neben Wittich MA, McWilliams RR, Halfdanarson T, Ma WW, Sio TT, Cleary SP, Truty MJ, Haddock MG, Hallemeier CL, Merrell KW. Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. J Gastrointest Oncol 2021;12:2275-86. [PMID: 34790392 DOI: 10.21037/jgo-21-55] [Reference Citation Analysis]
27 Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108-123. [PMID: 31705130 DOI: 10.1038/s41571-019-0281-6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 26.3] [Reference Citation Analysis]
28 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
29 Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.Front Oncol. 2020;10:41. [PMID: 32083002 DOI: 10.3389/fonc.2020.00041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
30 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Reference Citation Analysis]
31 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
32 Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 2021. [PMID: 34431604 DOI: 10.1002/ueg2.12123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kang JS, Choi YJ, Byun Y, Han Y, Kim JH, Lee JM, Sohn HJ, Kim H, Kwon W, Jang JY. Radiological tumour invasion of splenic artery or vein in patients with pancreatic body or tail adenocarcinoma and effect on recurrence and survival. Br J Surg 2021:znab357. [PMID: 34718433 DOI: 10.1093/bjs/znab357] [Reference Citation Analysis]
34 Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu JK, Kim YT, Oh DY, Chie EK, Jang JY. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34581022 DOI: 10.1002/jhbp.1050] [Reference Citation Analysis]
35 Maharaj AD, Evans SM, Ioannou LJ, Croagh D, Earnest A, Holland JF, Pilgrim CHC, Neale RE, Goldstein D, Kench JG, Merrett ND, White K, Burmeister EA, Evans PM, Hayes TM, Houli N, Knowles B, Leong T, Nikfarjam M, Philip J, Quinn M, Shapiro J, Smith MD, Spillane JB, Wong R, Zalcberg JR. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. HPB (Oxford) 2021:S1365-182X(21)01700-7. [PMID: 34852933 DOI: 10.1016/j.hpb.2021.11.005] [Reference Citation Analysis]
36 Fancellu A, Petrucciani N, Porcu A, Deiana G, Sanna V, Ninniri C, Perra T, Celoria V, Nigri G. The Impact on Survival and Morbidity of Portal-Mesenteric Resection During Pancreaticoduodenectomy for Pancreatic Head Adenocarcinoma: A Systematic Review and Meta-Analysis of Comparative Studies. Cancers (Basel). 2020;12. [PMID: 32698500 DOI: 10.3390/cancers12071976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019;111:782-94. [PMID: 31086963 DOI: 10.1093/jnci/djz073] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 38.5] [Reference Citation Analysis]
38 Janssen BV, Theijse R, van Roessel S, de Ruiter R, Berkel A, Huiskens J, Busch OR, Wilmink JW, Kazemier G, Valkema P, Farina A, Verheij J, de Boer OJ, Besselink MG. Artificial Intelligence-Based Segmentation of Residual Tumor in Histopathology of Pancreatic Cancer after Neoadjuvant Treatment. Cancers (Basel) 2021;13:5089. [PMID: 34680241 DOI: 10.3390/cancers13205089] [Reference Citation Analysis]
39 Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4326. [PMID: 34503138 DOI: 10.3390/cancers13174326] [Reference Citation Analysis]
40 Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:932-42. [PMID: 31339530 DOI: 10.1001/jamasurg.2019.2277] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
41 McCarthy PM, Rendo MJ, Uy MD, Adams AM, O'Shea AE, Nelson DW, Fenderson JL, Cebe KM, Krell RW, Clifton GT, Peoples GE, Vreeland TJ. Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. Onco Targets Ther 2021;14:3537-44. [PMID: 34103944 DOI: 10.2147/OTT.S311661] [Reference Citation Analysis]
42 Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Sekimoto M. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Surg Today 2020;50:335-43. [PMID: 31993761 DOI: 10.1007/s00595-020-01963-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
44 Yang L, Bai Y, Li Q, Chen J, Liu F, Weng X, Xu F. Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Front Oncol 2021;11:695645. [PMID: 34485131 DOI: 10.3389/fonc.2021.695645] [Reference Citation Analysis]
45 Yamada D, Takahashi H, Asukai K, Hasegawa S, Tomokuni A, Wada H, Akita H, Yasui M, Miyata H, Ishikawa O. Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of "pCR" from the prognostic standpoint. Ann Gastroenterol Surg 2019;3:676-85. [PMID: 31788656 DOI: 10.1002/ags3.12288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
46 Tomimaru Y, Eguchi H, Iwagami Y, Akita H, Noda T, Gotoh K, Kobayashi S, Nagano H, Mori M, Doki Y. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Cancer Chemother Pharmacol 2020;85:537-45. [PMID: 31834436 DOI: 10.1007/s00280-019-04005-y] [Reference Citation Analysis]
47 Cloyd JM, Tsung A, Hays J, Wills CE, Bridges JF. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. World J Gastroenterol 2020; 26(4): 375-382 [PMID: 32063686 DOI: 10.3748/wjg.v26.i4.375] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
48 Bispo M, Marques S, Rio-Tinto R, Fidalgo P, Devière J. The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine. GE Port J Gastroenterol 2021;28:111-20. [PMID: 33791398 DOI: 10.1159/000509197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Pan L, Fang J, Tong C, Chen M, Zhang B, Juengpanich S, Wang Y, Cai X. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;18:1. [PMID: 31892339 DOI: 10.1186/s12957-019-1767-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
50 Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, Williams T, Abushahin L, Bridges JFP, Santry H. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020;9. [PMID: 32326559 DOI: 10.3390/jcm9041129] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
51 Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J Gastrointest Surg 2019;23:112-21. [PMID: 30242644 DOI: 10.1007/s11605-018-3966-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
52 van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers (Basel) 2019;11:E93. [PMID: 30650521 DOI: 10.3390/cancers11010093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
53 Hsu DS, Kumar NS, Le ST, Chang AL, Kazantsev G, Spitzer AL, Peng PD, Chang CK. Centralization of pancreatic cancer treatment within an integrated healthcare system improves overall survival. Am J Surg 2021:S0002-9610(21)00562-6. [PMID: 34607651 DOI: 10.1016/j.amjsurg.2021.09.036] [Reference Citation Analysis]
54 Lewis S, Sastri SC, Arya S, Mehta S, Patil P, Shrivastava S, Phurailatpam R, Shrikhande SV, Engineer R. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. J Gastrointest Oncol 2019;10:474-82. [PMID: 31183197 DOI: 10.21037/jgo.2019.01.25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hermann RM, Christiansen H. [Preoperative radiochemotherapy improves oncological results in borderline resectable pancreatic cancer, but not overall survival in resectable cancers : Results from the Dutch PREOPANC study]. Strahlenther Onkol 2021;197:85-8. [PMID: 33258046 DOI: 10.1007/s00066-020-01717-6] [Reference Citation Analysis]
56 Saharia A, Potter L, Baio F, Elshawwaf M, Abdelrahim M, Heyne K. Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol 2020;43:753-4. [PMID: 32969854 DOI: 10.1097/COC.0000000000000743] [Reference Citation Analysis]
57 Tang R, Meng Q, Wang W, Liang C, Hua J, Xu J, Yu X, Shi S. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. Gland Surg 2021;10:1564-75. [PMID: 34164301 DOI: 10.21037/gs-21-16] [Reference Citation Analysis]
58 Heckler M, Hackert T. Surgery for locally advanced pancreatic ductal adenocarcinoma-is it only about the vessels? J Gastrointest Oncol 2021;12:2503-11. [PMID: 34790411 DOI: 10.21037/jgo-20-313] [Reference Citation Analysis]
59 Aaltonen P, Carpén O, Mustonen H, Puolakkainen P, Haglund C, Peltola K, Seppänen H. Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. Eur J Surg Oncol 2021:S0748-7983(21)00925-2. [PMID: 34844817 DOI: 10.1016/j.ejso.2021.11.116] [Reference Citation Analysis]
60 Okada K, Uemura K, Kondo N, Sumiyoshi T, Seo S, Otsuka H, Serikawa M, Ishii Y, Tsuboi T, Murakami Y, Takahashi S. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Langenbecks Arch Surg 2021. [PMID: 34609618 DOI: 10.1007/s00423-021-02339-x] [Reference Citation Analysis]
61 Hirokawa F, Ueno M, Nakai T, Kaibori M, Nomi T, Iida H, Tanaka S, Komeda K, Hayami S, Kosaka H, Hokuto D, Kubo S, Uchiyama K. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study. J Gastrointest Surg 2021. [PMID: 34664190 DOI: 10.1007/s11605-021-05175-y] [Reference Citation Analysis]
62 Ryckman JM, Reames BN, Klute KA, Hall WA, Baine MJ, Abdel-Wahab M, Lin C. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Clin Transl Radiat Oncol 2021;28:124-8. [PMID: 33981865 DOI: 10.1016/j.ctro.2021.04.002] [Reference Citation Analysis]
63 Milella M, Bassi C, Boggi U, Brunetti O, Cavaliere A, Crippa S, De Vita F, Falconi M, Frassineti GL, Giommoni E, Macchini M, Malleo G, Silvestris N, Tudisco A, Vasile E, Reni M. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Crit Rev Oncol Hematol 2021;169:103571. [PMID: 34923121 DOI: 10.1016/j.critrevonc.2021.103571] [Reference Citation Analysis]
64 Kamarajah SK, Naffouje SA, Salti GI, Dahdaleh FS. Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. Ann Surg Oncol 2021;28:1896-905. [PMID: 33398644 DOI: 10.1245/s10434-020-09470-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Trinh KV, Fischer DA, Gardner TB, Smith KD. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Front Oncol 2020;10:1461. [PMID: 33042792 DOI: 10.3389/fonc.2020.01461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
67 Imamura M, Nagayama M, Kyuno D, Ota S, Murakami T, Kimura A, Yamaguchi H, Kato T, Kimura Y, Takemasa I. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:2285. [PMID: 34064540 DOI: 10.3390/cancers13102285] [Reference Citation Analysis]
68 Ratnayake B, Savastyuk AY, Nayar M, Wilson CH, Windsor JA, Roberts K, French JJ, Pandanaboyana S. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. J Clin Med 2020;9:E2132. [PMID: 32640720 DOI: 10.3390/jcm9072132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
69 Vernuccio F, Messina C, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics (Basel) 2021;11:2166. [PMID: 34829513 DOI: 10.3390/diagnostics11112166] [Reference Citation Analysis]
70 Akita H, Takahashi H, Eguchi H, Asukai K, Hasegawa S, Wada H, Iwagami Y, Yamada D, Tomimaru Y, Noda T, Gotoh K, Kobayashi S, Doki Y, Sakon M. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study. Ann Gastroenterol Surg 2021;5:381-9. [PMID: 34095729 DOI: 10.1002/ags3.12418] [Reference Citation Analysis]
71 Nigri G, Petrucciani N, Belloni E, Lucarini A, Aurello P, D'Angelo F, di Saverio S, Fancellu A, Ramacciato G. Distal Pancreatectomy with Celiac Axis Resection: Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1967. [PMID: 33921838 DOI: 10.3390/cancers13081967] [Reference Citation Analysis]
72 Lee W, Park Y, Kwon JW, Jun E, Song KB, Lee JH, Hwang DW, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY, Park SY, Kim SC. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. J Clin Med 2020;9:E1477. [PMID: 32423123 DOI: 10.3390/jcm9051477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kurdia KC, Kapoor VK. Pancreatic Cancer: "Whether to Cross the Border"? Indian J Surg Oncol 2021;12:235-7. [PMID: 34295062 DOI: 10.1007/s13193-021-01341-5] [Reference Citation Analysis]
74 Hamad A, Brown ZJ, Ejaz AM, Dillhoff M, Cloyd JM. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. World J Gastroenterol 2021; 27(27): 4383-4394 [PMID: 34366611 DOI: 10.3748/wjg.v27.i27.4383] [Reference Citation Analysis]
75 Bhogal RH, Pericleous S, Khan AZ. Open and Minimal Approaches to Pancreatic Adenocarcinoma. Gastroenterol Res Pract 2020;2020:4162657. [PMID: 32565781 DOI: 10.1155/2020/4162657] [Reference Citation Analysis]
76 Patel SH, Katz MHG, Ahmad SA. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:4104-29. [PMID: 34047859 DOI: 10.1245/s10434-021-10075-1] [Reference Citation Analysis]
77 Nakamura T, Asano T, Okamura K, Tsuchikawa T, Murakami S, Kurashima Y, Ebihara Y, Noji T, Nakanishi Y, Tanaka K, Shichinohe T, Hirano S. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? J Gastrointest Surg 2019;23:990-6. [PMID: 30242645 DOI: 10.1007/s11605-018-3972-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
78 Okada Y, Nishiwada S, Yamamura K, Sho M, Baba H, Takayama T, Goel A. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Eur J Cancer 2021;146:125-34. [PMID: 33607476 DOI: 10.1016/j.ejca.2020.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Kang MJ, Kim SW. Paradigm shift for defining the resectability of pancreatic cancer. Ann Hepatobiliary Pancreat Surg 2021;25:451-5. [PMID: 34845115 DOI: 10.14701/ahbps.2021.25.4.451] [Reference Citation Analysis]
80 Chaudhari VA, Mitra A, Gupta V, Ostwal V, Ramaswamy A, Engineer R, Sirohi B, Shetty N, Bal M, Desouza A, Bhandare MS, Shrikhande SV. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence. Surgery 2021. [DOI: 10.1016/j.surg.2021.10.018] [Reference Citation Analysis]
81 Zheng R, Wang C, Huang X, Lin Q, Huang D, Li XB, Huang H, Xu B. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial. BMJ Open 2020;10:e039900. [PMID: 33154057 DOI: 10.1136/bmjopen-2020-039900] [Reference Citation Analysis]
82 Kimura N, Yamada S, Takami H, Murotani K, Yoshioka I, Shibuya K, Sonohara F, Hoshino Y, Hirano K, Watanabe T, Baba H, Mori K, Miwa T, Kanda M, Hayashi M, Matsui K, Okumura T, Kodera Y, Fujii T. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Cancers (Basel) 2020;13:E36. [PMID: 33374369 DOI: 10.3390/cancers13010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Nappo G, Donisi G, Zerbi A. Borderline resectable pancreatic cancer: Certainties and controversies. World J Gastrointest Surg 2021; 13(6): 516-528 [PMID: 34194610 DOI: 10.4240/wjgs.v13.i6.516] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Vietsch EE, Peran I, Suker M, van den Bosch TPP, van der Sijde F, Kros JM, van Eijck CHJ, Wellstein A. Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Appl Sci (Basel) 2019;9:4784. [PMID: 34484811 DOI: 10.3390/app9224784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Soer EC, Verbeke CS. Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties. J Gastrointest Oncol 2021;12:2512-20. [PMID: 34790412 DOI: 10.21037/jgo-20-391] [Reference Citation Analysis]
86 He C, Huang X, Zhang Y, Cai Z, Lin X, Li S. A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. Front Oncol 2019;9:1197. [PMID: 31781499 DOI: 10.3389/fonc.2019.01197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
87 Yoo C, Hwang I, Song TJ, Lee SS, Jeong JH, Park DH, Seo DW, Lee SK, Kim MH, Byun JH, Park JH, Hwang DW, Song KB, Lee JH, Lee W, Chang HM, Kim KP, Kim SC, Ryoo BY. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.Ther Adv Med Oncol. 2020;12:1758835920953294. [PMID: 32983266 DOI: 10.1177/1758835920953294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Unno M, Hata T, Motoi F. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today. 2019;49:295-299. [PMID: 30877550 DOI: 10.1007/s00595-019-01786-w] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
89 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Reference Citation Analysis]
90 Nooijen LE, Franken LC, Belkouz A, Oulad Abdennabi I, Besselink MG, Busch OR, Swijnenburg RJ, Klümpen HJ, Erdmann JI. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study. Am J Clin Oncol 2021;44:526-32. [PMID: 34469345 DOI: 10.1097/COC.0000000000000861] [Reference Citation Analysis]
91 Choi YJ, Byun Y, Kang JS, Kim HS, Han Y, Kim H, Kwon W, Oh DY, Paik WH, Lee SH, Ryu JK, Kim YT, Lee K, Chie EK, Jang JY. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut Liver. 2020;. [PMID: 32839360 DOI: 10.5009/gnl20070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ichikawa K, Mizuno S, Hayasaki A, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Usui M, Sakurai H, Isaji S. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients. Cancers (Basel). 2019;11. [PMID: 30974894 DOI: 10.3390/cancers11040514] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
93 Shinde RS, Bhandare M, Chaudhari V, Shrikhande SV. Cutting-edge strategies for borderline resectable pancreatic cancer. Ann Gastroenterol Surg 2019;3:368-72. [PMID: 31346575 DOI: 10.1002/ags3.12254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
94 Ikuta S, Sonoda T, Aihara T, Yamanaka N. A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma. Ann Transl Med. 2019;7:461. [PMID: 31700897 DOI: 10.21037/atm.2019.08.35] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
95 Hackert T. Surgery for Pancreatic Cancer after neoadjuvant treatment. Ann Gastroenterol Surg 2018;2:413-8. [PMID: 30460344 DOI: 10.1002/ags3.12203] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
96 Kim HS, Nakagawa K, Akahori T, Nakamura K, Takagi T, Sho M, Park JS, Yoon DS. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? J Clin Med 2021;10:873. [PMID: 33672686 DOI: 10.3390/jcm10040873] [Reference Citation Analysis]
97 Miccio JA, Talcott WJ, Patel T, Park HS, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, Jabbour SK, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clin Transl Radiat Oncol 2021;27:15-23. [PMID: 33392398 DOI: 10.1016/j.ctro.2020.12.003] [Reference Citation Analysis]
98 Navez J, Bouchart C, Lorenzo D, Bali MA, Closset J, van Laethem JL. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Ann Surg Oncol 2021. [PMID: 33479866 DOI: 10.1245/s10434-020-09568-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Curr Oncol 2019;26:e665-81. [PMID: 31708660 DOI: 10.3747/co.26.5193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Sugawara T, Ban D, Nishino J, Watanabe S, Maekawa A, Ishikawa Y, Akahoshi K, Ogawa K, Ono H, Kudo A, Tanaka S, Tanabe M. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. PLoS One 2021;16:e0249885. [PMID: 33844700 DOI: 10.1371/journal.pone.0249885] [Reference Citation Analysis]
101 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Klaiber U, Hackert T. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. Front Oncol. 2019;9:1501. [PMID: 31993372 DOI: 10.3389/fonc.2019.01501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
103 Mataki Y, Kurahara H, Idichi T, Tanoue K, Hozaka Y, Kawasaki Y, Iino S, Maemura K, Shinchi H, Ohtsuka T. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Cancers (Basel) 2021;13:1057. [PMID: 33801465 DOI: 10.3390/cancers13051057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, van Eijck CHJ, de Hingh IHJT, Karsten TM, van der Kolk MB, Patijn GA, Liem MSL, van Santvoort HC, Loosveld OJL, de Vos-Geelen J, Zonderhuis BM, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021;21:300. [PMID: 33757440 DOI: 10.1186/s12885-021-08031-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
105 Lof S, Korrel M, van Hilst J, Alseidi A, Balzano G, Boggi U, Butturini G, Casadei R, Dokmak S, Edwin B, Falconi M, Keck T, Malleo G, de Pastena M, Tomazic A, Wilmink H, Zerbi A, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. Ann Surg Oncol 2020;27:1986-96. [PMID: 31848815 DOI: 10.1245/s10434-019-08137-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
106 Iyengar S, Nevala-Plagemann C, Garrido-Laguna I. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Ther Adv Med Oncol 2021;13:17588359211045861. [PMID: 34552668 DOI: 10.1177/17588359211045861] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Choi YH, Lee SH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT, Kwon W, Jang JY, Kim SW. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Gut Liver 2021;15:315-23. [PMID: 32235008 DOI: 10.5009/gnl19182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Anger F, Döring A, van Dam J, Lock JF, Klein I, Bittrich M, Germer CT, Wiegering A, Kunzmann V, van Eijck C, Löb S. Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. Ann Surg Oncol 2021;28:2325-36. [PMID: 32920720 DOI: 10.1245/s10434-020-09100-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
109 Reddy AV, Hill CS, Sehgal S, He J, Zheng L, Herman JM, Meyer J, Narang AK. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00500-8. [PMID: 34974972 DOI: 10.1016/j.clon.2021.12.014] [Reference Citation Analysis]
110 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
111 Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol 2021;12:2475-83. [PMID: 34790408 DOI: 10.21037/jgo-21-119] [Reference Citation Analysis]
112 Tezuka K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Todaka A, Fukutomi A, Uesaka K. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Pancreatology 2021;21:1451-9. [PMID: 34462214 DOI: 10.1016/j.pan.2021.08.009] [Reference Citation Analysis]
113 Windsor JA. Biomarkers Urgently Needed to Advance Treatment Decisions for Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:e190502. [PMID: 30942878 DOI: 10.1001/jamasurg.2019.0502] [Reference Citation Analysis]
114 Kondo N, Uemura K, Sudo T, Hashimoto Y, Sumiyoshi T, Okada K, Seo S, Otsuka H, Murakami Y, Takahashi S. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Eur J Cancer 2021;159:215-23. [PMID: 34781169 DOI: 10.1016/j.ejca.2021.10.012] [Reference Citation Analysis]
115 Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. JAMA Surg 2019;154:e190484. [PMID: 30942874 DOI: 10.1001/jamasurg.2019.0484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
116 Hwang HK, Wada K, Kim HY, Nagakawa Y, Hijikata Y, Kawasaki Y, Nakamura Y, Lee LS, Yoon DS, Lee WJ, Kang CM. A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy. Chin J Cancer Res 2020;32:105-14. [PMID: 32194310 DOI: 10.21147/j.issn.1000-9604.2020.01.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
118 Inoue Y, Oba A, Ono Y, Sato T, Ito H, Takahashi Y. Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy-Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers (Basel) 2021;13:1818. [PMID: 33920314 DOI: 10.3390/cancers13081818] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Silvestris N, Brunetti O, Bittoni A, Cataldo I, Corsi D, Crippa S, D'Onofrio M, Fiore M, Giommoni E, Milella M, Pezzilli R, Vasile E, Reni M. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2020;12:E1681. [PMID: 32599886 DOI: 10.3390/cancers12061681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
120 Kim N, Han IW, Ryu Y, Hwang DW, Heo JS, Choi DW, Shin SH. Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors. Cancers (Basel) 2020;12:E137. [PMID: 31935830 DOI: 10.3390/cancers12010137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, de Wilde RF, Wilmink JW, van Eijck CHJ, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Eur J Cancer 2022;160:140-9. [PMID: 34838371 DOI: 10.1016/j.ejca.2021.10.023] [Reference Citation Analysis]
122 Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer 2021;21:936. [PMID: 34412605 DOI: 10.1186/s12885-021-08666-y] [Reference Citation Analysis]
123 Delpero JR, Sauvanet A. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Front Oncol 2020;10:40. [PMID: 32117714 DOI: 10.3389/fonc.2020.00040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
124 Choi MH, Yoon SB, Song M, Lee IS, Hong TH, Lee MA, Jung ES. Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. PLoS One 2020;15:e0240318. [PMID: 33027288 DOI: 10.1371/journal.pone.0240318] [Reference Citation Analysis]
125 Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, Mittler J, Lang H, Lutz MP, Lesurtel M;  Scientific and Research Committee of the E-AHPBA and the EORTC pancreas working group. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19:675. [PMID: 31288786 DOI: 10.1186/s12885-019-5889-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
126 Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery? J Gastrointest Oncol 2021;12:2450-60. [PMID: 34790406 DOI: 10.21037/jgo-2020-slapc-04] [Reference Citation Analysis]
127 Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H, Goel A. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Gastroenterology 2020;159:562-74. [PMID: 32376411 DOI: 10.1053/j.gastro.2020.04.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
128 Read GH, Bailleul J, Vlashi E, Kesarwala AH. Metabolic response to radiation therapy in cancer. Mol Carcinog 2021. [PMID: 34961986 DOI: 10.1002/mc.23379] [Reference Citation Analysis]
129 Lee YS, Lee JC, Yang SY, Kim J, Hwang JH. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. Sci Rep 2019;9:15662. [PMID: 31666626 DOI: 10.1038/s41598-019-52167-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
130 Hu Q, Wang D, Chen Y, Li X, Cao P, Cao D. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Radiat Oncol. 2019;14:120. [PMID: 31291998 DOI: 10.1186/s13014-019-1330-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
131 Naito Y, Ishikawa H, Sadashima E, Okabe Y, Takahashi K, Kawahara R, Hisaka T, Fukahori M, Ushijima T, Ishida Y, Tanigawa M, Mihara Y, Nakayama M, Kondo R, Kusano H, Takase Y, Abe H, Ogo E, Okuda K, Shimamatsu K, Yano H, Akiba J. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis. Mol Clin Oncol 2019;11:225-33. [PMID: 31423309 DOI: 10.3892/mco.2019.1885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Ann Gastroenterol Surg 2020;4:100-8. [PMID: 32258974 DOI: 10.1002/ags3.12311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
133 Søreide K. Heterogeneity in neoadjuvant therapy for localized pancreatic cancer: a persisting radiant autonomy. Hepatobiliary Surg Nutr 2021;10:254-6. [PMID: 33898570 DOI: 10.21037/hbsn-2020-9] [Reference Citation Analysis]
134 Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4724. [PMID: 34572951 DOI: 10.3390/cancers13184724] [Reference Citation Analysis]
135 Scheufele F, Hartmann D, Friess H. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/Locally advanced pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:32. [PMID: 31231699 DOI: 10.21037/tgh.2019.04.09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]